ROPE MICROCAP R

European Microcaps

ISIN LU1303940784

9%

MONTHLY REPORT JUNE 28.2024

Risk profile Morningstar™



-4.5%	+4.1%	11.9%
Performance	Performance	Volatility
1 month	YTD	1 year
Bench.	Bench.	Bench.
-3.7%	+3.8%	10.2%





The European stock markets ended down in June. The dissolution of the French National Assembly after the European elections weighed on the French stocks in a context of widening credit spreads. We would nevertheless note that France represents only around 11% of our European index. Additionally, the ECB lowered (as expected) its key rates at the beginning of June and inflation in the United States appears to be continuing to gradually stabilise. Over the month, the MSCI Europe fell -1.0%, the MSCI Europe Smallcap -3.3%, the MSCI Europe Microcap -3.3% and the MSCI Europe ex UK Microcap -4.1%. With 148 of the 205 portfolio stocks down, the fund slightly underperformed its benchmark index. Among the best contributors, we would note KUROS BIOSCIENCES (+27%), which is continuing to show good operating momentum, and NORBIT (+21%), which announced a strategic acquisition. In contrast, KAUFMAN & BROAD (-23%) and OSE IMMUNO (-34%) were affected by the political context while TRACSIS (-23%) was hit by the downward revision in its 2024 objectives.

Concerning the principal portfolio movements, we sold CADELER, which hit our maximum market capitalisation of €2bn, and VOYAGEURS DU MONDE, where we profited from a buyback offer for 20% of the shares (16% premium). We took profits in CALLIDITAS, which received a bid from Asahi Kasei (80% premium). Additionally, we initiated positions in EPENDION, whose momentum appears to be reviving, ROSENBAUER, world leader in equipment for firefighters whose balance sheet should be reinforced, and R&S GROUP, that is being boosted by substantial orders. On the extra-financial level, R&S Group uses 80% recyclable raw materials in its electrical transformers. The group has drawn up an ESG roadmap whose objectives will be integrated into the makeup of the remuneration of its top managers.

Main transactions over the month

(+) EPENDION (+) R&S GROUP

(-) CADELER

(+) ROSENBAUER INT

(-) CALLIDITAS

(-) VOYAGEURS DU MONDE

(+) New holding (-) Sale

Major contributors/detractors over the month (%)

KUROS BIOSCIENCES +0.2 AUMANN AG XPS PENSIONS KAUFMAN & BROA ... -0.2 +0.1 NORBIT ASA +0.1 OSE IMMUNO

Mandarine Europe Microcap invests in the smallest European market capitalisations, applying a quantitative screening filter followed by fundamental stock analysis, designed to detect those stocks which offer the most favourable risk/return profile. The fund has been awarded the French SRI label.


PERFORMANCES AND RISKS

The data presented relates to past periods, past performance is not an indicator of future results. Statistical indicators are calculated on a weekly basis.

Benchmark: Stoxx Small 200 NR until 31/08/2015, MSCI Europe Microcap NR until 31/12/2020, 50% MSCI Europe Microcap + 50% MSCI Europe ex-UK Microcap NR since 01/01/2021.



Bench. Fund 35% +31.2 23.8 +17.8 +18.7



Rolling / annualized performances

Annual performances

Rolling performances				Annualized performance					
	1 month	YTD	1 year	3 years	5 years	Inception	3 years	5 years	Inception
Fund	-4.5%	+4.1%	+6.1%	-14.4%	+42.0%	+142.7%	-5.0%	+7.3%	+8.8%
Bench.	-3.7%	+3.8%	+4.3%	-21.2%	+23.7%	+81.6%	-7.6%	+4.3%	+5.9%
Diff.	-0.8%	+0.3%	+1.7%	+6.8%	+18.3%	+61.0%	+2.6%	+2.9%	+3.0%
Quartile*	3	2	2	3	1	1			

^{*}Morningstar - Europe Equity Small Cap

Risk indicators

	Fund volatility	Benchmark volatility	Tracking error	Information ratio	Sharpe ratio
1 year	11.9%	10.2%	3.7%	0.5	0.2
3 years	14.2%	12.5%	3.8%	0.7	-0.5

MANDARINE

EUROPE MICROCAP R



PORTFOLIO STRUCTURE

Main holdings 📙			
	Weight	ESG-Mid	cro Rating (±2)
VOLUTION GROUP PLC	0.8%	-	Industrials / Great-Britain
PROTECTOR FORSIKRING	0.8%	-	Financials / Norway
RENEW HOLDINGS PLC	0.7%	-	Industrials / Great-Britain
XPS PENSIONS GROUP PLC	0.7%	-	Financials / Great-Britain
SIGMAROC PLC	0.7%	-	Materials / Great-Britain
PREVAS AB-B SHS	0.7%	-	Technology / Sweden
TRISTEL PLC	0.7%	-	Health Care / Great-Britain
BLOOMSBURY PUBLISHING P	0.7%	-	Telecom / Great-Britain
TUBACEX SA	0.7%	-	Materials / Spain
ORIGIN ENTERPRISES PLC	0.7%	-	Cons.Staples / Ireland

Sector		Country	
Industrials	20.2%	Sweden	20.1%
Technology	17.6%	Great-Britain	17.0%
Health Care	15.0%	France	9.5%
Financials	13.7%	Germany	9.4%
Cons. Discretionary	9.0%	Norway	9.3%
Real Estate	5.3%	Italy	6.9%
Materials	4.7%	Finland	5.4%
Cons.Staples	4.0%	Switzerland	4.6%
Telecom	3.9%	Denmark	3.8%
Energy	3.8%	Belgium	3.6%
Utilities	1.2%	Spain	2.3%
Cash & Others	1.5%	Ireland	1.6%
		Netherlands	1.6%
		Other Country	2.2%

FUND PROFILE

Key figures at June 28 2024

Asset under management	200.8M€
Equity exposure	98.6%
Number of holdings	205
Active share	79.5%
Average capitalisation (Bln €)	0.43
EPS growth (Next 12 M./Last 12 M.)	+16.6%
PE (Next 12 Months)	13.1x


ESG profile



168









1.5%

Cash & Others

EUR	44.1%
SEK	20.6%
GBP	17.3%
NOK	10.0%
CHF	4.6%
51414	

^{*}Tonnes of CO2e/M€ invested, Direct (scope 1-2) + First tier indirect



CHARACTERISTICS

ISIN	Bloomberg code MANEMRE LX Equity	Inception of the fund	Shareclass inception
LU1303940784		31/12/2013	31/12/2013
Legal Status	Shareclass currency	Investment horizon	Management company
Sicav Lux.	EUR	5 years	Mandarine Gestion
Depositary	Valuation	Cut-Off	Settlement
BNP Paribas	Daily	13h00	D+2
Management Fee	Performance Fee 20% of the outperformance over the benchmark if perf > 0	Initial charge	Redemption Fee
1.95%		2.00%	0%



Mandarine Gestion 30 avenue Kléber | 75016 Paris www.mandarine-gestion.com

DISCLAIMER

The purpose of this document is to present, for information purposes only, the characteristics of Mandarine Gestion products. It in no manner constitutes a sale or subscription offer. The indices cited in this document are based on net dividends reinvested ("NR"). The described performances on to take into account fees and costs potentially charged in connection with the subscription or redemption of fund units. This document has been drawn up for information purposes only and does not constitute an offer or personalised recommendation or a solicitation to subscribe to this product. The information, opinions and analyses contained in this document do not have any contractual value. Only the information contained in the KIID and prospectus is legally binding. The prospectus is available on simple demand from Mandarine Gestion and is available on the www.mandarinegestion.com website. Your money will be principally invested in financial instruments Gestion and is available on the www.mandarinegestion.com website. Your money will be principally invested in financial instruments elected by the management company. These instruments will be subject to market fluctuations and uncertainties. Past performances do not guarantee future performances. Performances are notably not constant over time. The performance data mentioned in the document does not take into account fees and charges assessed in connection with the issue and redemption of units or shares and does not include taxes imposed by the country of residence of the client. The UCITS is exclusively destined for sale to residents of those countries in which the UCITS is registered. Sales in jurisdictions other than those countries in which the UCITS is registered.

sale to residents of those countries in which the UCITS is registered. Sales in jurisdictions other than those countries in which the UCITS is registered are not authorised.

RISK PROFILE - RISKS ASSOCIATED WITH THE PRODUCT

Risk of capital loss, equity market risk, risk linked to the ownership of small and midcaps, interest rate risk, credit risk and discretionary management risk, and to a lesser extent emerging market risk, counterparty risk and exchange rate risk. The descriptions and details are included in the complete prospectus of the UCITS. Investors are invited to read the prospectus in order to obtain detailed information regarding the risks to which the fund is exposed prior to any investment decision. This product does not offer any guarantee as to returns or the capital invested, which may not be entirely returned.